Philadelphia chromosome-negative acute lymphoblastic leukemia: Therapies under development

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2201-2212

  Parikh, Sameer A ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

chimeric antigen receptor therapy; immunotoxin; NOTCH1 inhibitors; novel monoclonal antibodies; proteasome inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; BLINATUMOMAB; CD19 ANTIBODY; CD20 ANTIBODY; CD22 ANTIGEN; CD52 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; MK 0752; MONOCLONAL ANTIBODY; NELARABINE; NOTCH1 RECEPTOR; NUCLEOSIDE ANALOG; OFATUMUMAB; PROTEASOME INHIBITOR; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER CHEMOTHERAPY; CELL LINEAGE; CELL MIGRATION; DISEASE FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

HUMANS; MOLECULAR TARGETED THERAPY; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84916614031     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.81     Document Type: Review

References (65)

1. Thomas DA, O'Brien S, Faderl S et al. Chemoimmunotherapy with a modifed hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 28(24), 3880-3889 (2010).
2. Pui CH, Pei D, Campana D et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J. Clin. Oncol. 29(4), 386-391 (2011).
3. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 106(12), 2657-2663 (2006).
4. Rowe JM, Buck G, Burnett AK et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106(12), 3760-3767 (2005).
5. Stock W, Johnson JL, Stone RM et al. Dose intensifcation of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 119(1), 90-98 (2013).
6. Litzow MR. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am. Soc. Clin. Oncol. Educ. Book 294-299 (2013).
7. Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr. Opin. Oncol. 25 (6), 701-706 (2013).
8. Raponi S, De Propris MS, Intoppa S et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 52 (6), 1098-1107 (2011).
9. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J. Clin. Oncol. 30(31), 3876-3883 (2012).
10. + patients studied prospectively in GMALL study 07/2003. ASH Annu. Meet. Abstracts 116(21), 170 (2010).
11. Topp MS, Gokbuget N, Zugmaier G et al. Long-term follow-up of hematologic relapse-free survival in a Phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26), 5185-5187 (2012).
12. Topp MS, Goekbuget N, Zugmaier G et al. PhaseII trial of the anti-CD 19 bispecifc T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractoryB-precursor acute lymphoblastic leukemia. J. Clin. Oncol. pii: J CO. 2014.56.3247 (2014) (Epub ahead of print).
13. Raetz EA, Cairo MS, Borowitz MJ et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study J. Clin. Oncol. 26(22), 3756-3762 (2008).
14. Advani A, Mcdonough S, Coutre S et al. Southwest Oncology Group Study S0910: a Phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. ASH Annu. Meet. Abstracts 120(21), 2603 (2012).
15. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a Phase 2 study. Lancet Oncol. 13(4), 403-411 (2012).
16. Deangelo D, Stock W, Petersdorf S et al. Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. ASH Annu. Meet. Abstracts 120(21), 2612 (2012).
17. Coiffer B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
18. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fudarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376 (9747), 1164-1174 (2010).
19. Buske C, Hoster E, Dreyling M et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23(1), 153-161 (2009).
20. Dworzak MN, Schumich A, Printz D et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112(10), 3982-3988 (2008).
21. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28(21), 3525-3530 (2010).
22. Jabbour EJ, Kantarjian H, Thomas D et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood 122(21), 2664 (2013).
23. Goede V, Fischer K, Busch R et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): fnal stage 2 results of the CLL11 trial. Blood 122(21), 6 (2013).
24. Ribrag V, Dupuis J, Tilly H et al. A Phase I study of sar3419, an anti-cd19 antibody maytansinoid conjugate, administered once weekly in patients with relapsed/refractory b-cell non hodgkin's lymphoma. Clin. Cancer Res. 20(1), 213-220 (2013).
25. Herrera L, Bostrom B, Gore L et al. A Phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31(12), 936-941 (2009).
26. Advani AS, Gundacker HM, Sala-Torra O et al. Southwest Oncology Group Study S0530: a Phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br. J. Haematol. 151(5), 430-434 (2010).
27. Thorson JS, Sievers EL, Ahlert J et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des. 6 (18), 1841-1879 (2000).
28. O'Brien S, Thomas DA, Jorgensen JL et al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL). ASH Annu. Meet. Abstracts 120(21), 671 (2012).
29. Wayne AS, Kreitman RJ, Findley HW et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and Phase I clinical trial. Clin. Cancer Res 16(6), 1894-1903 (2010).
30. Wayne AS, Bhojwani D, Silverman LB et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia (ALL). ASH Annu. Meet. Abstracts 118(21), 248 (2011).
31. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fudarabine: results of a large international study. Blood 99(10), 3554-3561 (2002).
32. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as frst-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616-5623 (2007).
33. Stock W, Sanford B, Lozanski G et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): fnal Phase I results of a Cancer and Leukemia Group B Study (CALGB 10102). ASH Annu. Meet. Abstracts 114(22), 838 (2009).
34. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 18(9), 1557-1558 (2004).
35. Tibes R, Keating MJ, Ferrajoli A et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12), 2645-2651 (2006).
36. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013).
37. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
38. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
39. Davila ML, Riviere I, Wang X et al. Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy. Blood 122(21), 69 (2013).
40. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65(1), 333-347 (2014).
41. Morgan RA, Chinnasamy N, Abate-Daga D et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36(2), 133-151 (2013).
42. O'Brien S, Schiller G, Lister J et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J. Clin. Oncol. 31(6), 676-683 (2013).
43. Roman-Gomez J, Jimenez-Velasco A, Barrios M et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk. Lymphoma 48(7), 1269-1282 (2007).
44. Vilas-Zornoza A, Agirre X, Martin-Palanco V et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS ONE 6(2), e17012 (2011).
45. Garcia-Manero G, Thomas DA, Rytting ME et al. Final report of a Phase I trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia (ALL). ASH Annu. Meet. Abstracts 116(21), 867 (2010).
46. Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 97(4), 427-430 (1999).
47. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23(3), 630-639 (2005).
48. Messinger YH, Gaynon PS, Sposto R et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 120(2), 285-290 (2012).
49. Filicko-O'hara J, Mookerjee B, Alpdogan O et al. Phase II study of bortezomib, mitoxantrone and etoposide in relapsed/refractory acute leukemias. ASH Annu. Meet. Abstracts 116(21), 2192 (2010).
50. Den Boer ML, Van Slegtenhorst M, De Menezes RX et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classifcation study. Lancet Oncol. 10(2), 125-134 (2009).
51. Mullighan CG, Su X, Zhang J et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360(5), 470-480 (2009).
52. Kg R, Li Y, Payne-Turner D et al. Genomic characterization and experimental modeling of BCR-ABL1-like acute lymphoblastic leukemia. Blood 122(21), 232 (2013).
53. Deangelo DJ, Yu D, Johnson JL et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109(12), 5136-5142 (2007).
54. Gökbuget N, Basara N, Baurmann H et al. High single-drug activity of nelarabine in relapsedT-lymphoblastic leukemia/lymphoma offers curative option with subsequent stemcell transplantation. Blood 118(13), 3504-3511 (2011).
55. Forcade E, Leguay T, Vey N et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol. Blood Marrow Transplant. 19(7), 1124-1126 (2013).
56. Hartz B, Lobel U, Hagel C, Escherich G. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am. J. Hematol. 88(12), 1096-1097 (2013).
57. Kawakami M, Taniguchi K, Yoshihara S et al. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine. Am. J. Hematol. 88(10), 853-857 (2013).
58. Gollard R P, Selco S. Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia. J. Clin. Oncol. 31(19), e327-e331 (2013).
59. Jain P, Kantarjian H, Ravandi F et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4), 973-975 (2013).
60. Tzoneva G, Ferrando AA. Recent advances on NOTCH signaling in T-ALL. Curr. Top Microbiol. Immunol. 360, 163-182 (2012).
61. Weng AP, Ferrando AA, Lee W et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694), 269-271 (2004).
62. Deangelo Dj SR, Silverman Lb et al. A Phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol. 24(Suppl), Abstract 6585 (2006).
63. Huguet F, Leguay T, Raffoux E et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 s t udy. J. Clin. Oncol. 27(6), 911-918 (2009).
64. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classifcation of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. J. Clin. Oncol. 31(34), 4333-4342 (2013).
65. Neumann M, Heesch S, Vosberg S et al. Mutational spectrum of adult T-ALL. Blood 122(21), 828 (2013).